ID   LN229/hPDPN
AC   CVCL_D2U6
RX   Patent=US10227407;
RX   PubMed=25080943;
RX   PubMed=26492619;
RX   PubMed=26937552;
RX   PubMed=27031228;
RX   PubMed=27328060;
RX   PubMed=27564251;
RX   PubMed=28101903;
RX   PubMed=28387591;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 29602; PDPN.
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Brain, right frontal parieto-occipital cortex.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0393 ! LN-229
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 30-01-24; Version: 1
//
RX   Patent=US10227407;
RA   Kato Y., Kaneko M.K.;
RT   "Anti-podoplanin antibody.";
RL   Patent number US10227407, 12-Mar-2019.
//
RX   PubMed=25080943; DOI=10.1038/srep05924;
RA   Kato Y., Kaneko M.K.;
RT   "A cancer-specific monoclonal antibody recognizes the aberrantly
RT   glycosylated podoplanin.";
RL   Sci. Rep. 4:5924-5924(2014).
//
RX   PubMed=26492619; DOI=10.1089/mab.2015.0018;
RA   Ogasawara S., Oki H., Kaneko M.K., Hozumi Y., Liu X., Honma R.,
RA   Fujii Y., Nakamura T., Goto K., Takagi M., Kato Y.;
RT   "Development of monoclonal antibody LpMab-10 recognizing
RT   non-glycosylated PLAG1/2 domain including Thr34 of human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 34:318-326(2015).
//
RX   PubMed=26937552; DOI=10.1089/mab.2015.0077;
RA   Kato Y., Ogasawara S., Oki H., Honma R., Takagi M., Fujii Y.,
RA   Nakamura T., Saidoh N., Kanno H., Umetsu M., Kamata S., Kubo H.,
RA   Yamada M., Sawa Y., Morita K.-i., Harada H., Suzuki H., Kaneko M.K.;
RT   "Novel monoclonal antibody LpMab-17 developed by CasMab technology
RT   distinguishes human podoplanin from monkey podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:109-116(2016).
//
RX   PubMed=27031228; DOI=10.1371/journal.pone.0152912;
RA   Kato Y., Ogasawara S., Oki H., Goichberg P., Honma R., Fujii Y.,
RA   Kaneko M.K.;
RT   "LpMab-12 established by CasMab technology specifically detects
RT   sialylated O-glycan on Thr52 of platelet aggregation-stimulating
RT   domain of human podoplanin.";
RL   PLoS ONE 11:E0152912-E0152912(2016).
//
RX   PubMed=27328060; DOI=10.1089/mab.2016.0006;
RA   Ogasawara S., Kaneko M.K., Honma R., Oki H., Fujii Y., Takagi M.,
RA   Suzuki H., Kato Y.;
RT   "Establishment of mouse monoclonal antibody LpMab-13 against human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:155-162(2016).
//
RX   PubMed=27564251; DOI=10.1089/mab.2016.0031;
RA   Ogasawara S., Kaneko M.K., Kato Y.;
RT   "LpMab-19 recognizes sialylated O-Glycan on Thr76 of human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 35:245-253(2016).
//
RX   PubMed=28101903; DOI=10.1002/cam4.954;
RA   Kaneko M.K., Nakamura T., Honma R., Ogasawara S., Fujii Y., Abe S.,
RA   Takagi M., Harada H., Suzuki H., Nishioka Y., Kato Y.;
RT   "Development and characterization of anti-glycopeptide monoclonal
RT   antibodies against human podoplanin, using glycan-deficient cell lines
RT   generated by CRISPR/Cas9 and TALEN.";
RL   Cancer Med. 6:382-396(2017).
//
RX   PubMed=28387591; DOI=10.1089/mab.2017.0001;
RA   Yamada S., Ogasawara S., Kaneko M.K., Kato Y.;
RT   "LpMab-23: a cancer-specific monoclonal antibody against human
RT   podoplanin.";
RL   Monoclon. Antib. Immunodiagn. Immunother. 36:72-76(2017).
//